Search Results - Andrea B. Apolo
- Showing 1 - 20 results of 51
- Go to Next Page
-
1
-
2
Targeted therapies in urothelial carcinoma by Monalisa Ghosh, Sam J. Brancato, Piyush K. Agarwal, Andrea B. Apolo
Published 2014Revisão -
3
Immunotherapy: a new treatment paradigm in bladder cancer by Nicole N. Davarpanah, Akira Yuno, Jane B. Trepel, Andrea B. Apolo
Published 2017Artigo -
4
Trimodality Therapy in Bladder Cancer by Christopher Premo, Andrea B. Apolo, Piyush K. Agarwal, Deborah E. Citrin
Published 2015Revisão -
5
Multimodal management of muscle-invasive bladder cancer by Jong‐Chul Park, Deborah E. Citrin, Piyush K. Agarwal, Andrea B. Apolo
Published 2014Revisão -
6
-
7
-
8
-
9
-
10
-
11
-
12
-
13
Prognostic Model for Predicting Survival of Patients With Metastatic Urothelial Cancer Treated With Cisplatin-Based Chemotherapy by Andrea B. Apolo, Irina Ostrovnaya, Susan Halabi, Alexia Iasonos, George Philips, Jonathan E. Rosenberg, Jamie C. Riches, Eric J. Small, Matthew I. Milowsky, Dean F. Bajorin
Published 2013Artigo -
14
-
15
Neoadjuvant Chemotherapy Use in Bladder Cancer: A Survey of Current Practice and Opinions by Nick G. Cowan, Yiyi Chen, Tracy M. Downs, Bernard H. Bochner, Andrea B. Apolo, Michael P. Porter, Jeffrey C. La Rochelle, Christopher L. Amling, Theresa M. Koppie
Published 2014Artigo -
16
-
17
Phase II Study of Gemcitabine, Carboplatin, and Bevacizumab in Patients With Advanced Unresectable or Metastatic Urothelial Cancer by Arjun Vasant Balar, Andrea B. Apolo, Irina Ostrovnaya, Svetlana Mironov, Alexia Iasonos, A. Trout, Ashley Marie Regazzi, Ilana Garcia-Grossman, David Gallagher, Matthew I. Milowsky, Dean F. Bajorin
Published 2013Artigo -
18
Advances in medical imaging for the diagnosis and management of common genitourinary cancers by Mohammadhadi Bagheri, Mark A. Ahlman, Liza Lindenberg, Barış Türkbey, Jeffrey Lin, A. Cahid Civelek, Ashkan A. Malayeri, Piyush K. Agarwal, Peter L. Choyke, Les Folio, Andrea B. Apolo
Published 2017Revisão -
19
Patient-reported outcomes with first-line nivolumab plus cabozantinib versus sunitinib in patients with advanced renal cell carcinoma treated in CheckMate 9ER: an open-label, rando... by David Cella, Robert J. Motzer, Cristina Suárez, Steven I. Blum, Flavia Ejzykowicz, Melissa Hamilton, Joel Wallace, Burçin Şimşek, Joshua Zhang, Cristina Ivanescu, Andrea B. Apolo, Toni K. Choueiri
Published 2022Artigo -
20
Ocular Adverse Events following Use of Immune Checkpoint Inhibitors for Metastatic Malignancies by Carl Noble, Sapna Gangaputra, Ian Thompson, Amy Yuan, Andrea B. Apolo, Jung‐Min Lee, George N. Papaliodis, Shilpa Kodati, Rachel Bishop, M. Teresa Magone, Lucia Sobrin, H. Nida Sen
Published 2019Artigo
Search Tools:
Related Subjects
Medicine
Internal medicine
Cancer
Oncology
Bladder cancer
Immunotherapy
Urology
Biology
Chemotherapy
Clinical trial
Nivolumab
Cabozantinib
Renal cell carcinoma
Genetics
Adverse effect
Cancer research
Prostate cancer
Urothelial carcinoma
Confidence interval
Gene
Metastatic Urothelial Carcinoma
Biochemistry
Cisplatin
Clinical endpoint
Disease
Gastroenterology
Hazard ratio
Sunitinib
Bioinformatics
Immunology